Cellebrite Q1 2026 Beats on All Fronts: AI Monetization Shift Opens Multi-Year Re-Rating Window

Event Summary

Cellebrite DI Ltd. (CLBT) delivered Q1 2026 results at or above the high end of prior guidance, according to official SEC 6-K filings and MarketBeat reporting. Revenue came in at $128.3M (+19% YoY), ARR reached $493M (+21% YoY), and Adjusted EBITDA hit $30.6M (+29% YoY) with an 86% gross margin. TTM free cash flow margin stood at 32% on $159M of FCF.

The qualitative inflection point: Genesis, Cellebrite's agentic AI product launched March 16, has attracted 500+ early users across 15+ countries ahead of its June general availability. Critically, the 2026 plan originally assumed zero AI-specific revenue — management has now revised this to include AI bookings starting Q2. Full-year guidance was reaffirmed at ARR of $567–$573M and revenue of $565–$571M, with Adjusted EBITDA of $149–$155M. FedRAMP High authorization (announced May 6) adds a structural federal pipeline tailwind, with U.S. federal ARR reportedly up ~35% YoY.

Leverage Impact Analysis

For traders using CoinUnited.io's stock CFD product — which offers up to 2000x leverage with zero fees — CLBT's earnings beat creates an asymmetric setup but demands careful position sizing given the stock's mid-cap liquidity profile.

Worked example: A trader opening a 50x long CLBT CFD post-earnings faces amplified exposure to any gap-up move. If CLBT rises 8% on the print, a 50x position yields a 400% return on margin — but a 2% adverse reversal erases the equivalent of a 100% margin loss. At 100x leverage, a mere 1% move against the position triggers a margin call equivalent to the full notional.

Key risk factors for leveraged longs:

• -GAAP net income declined YoY to $10.9M (from $17.4M) due to elevated opex and M&A integration — bears will anchor to this.
• -Q2 Adjusted EBITDA guidance of $29–$31M implies slight sequential compression from Q1's $30.6M.
• -A ~2 percentage point FX headwind is baked into Q2 guidance and could widen if USD strengthens.

Traders should monitor whether the post-earnings bid is sustained on volume — a gap-up with fading volume would signal profit-taking rather than a durable re-rating. Check open interest for confirmation signals on CoinUnited.io before sizing aggressively. For guidance on structuring earnings-driven trades, the earnings beat sector playbooks offer relevant frameworks.

Cross-Market Impact

CLBT's beat is micro-specific with limited direct macro spillover, but it carries thematic read-through across two areas:

AI-SaaS / GovTech peers: The Genesis narrative positions CLBT alongside government-AI analytics names. Palantir (PLTR) and Axon Enterprise (AXON) trade on similar law-enforcement and public-sector AI themes — positive CLBT sentiment can incrementally support these names. This fits the broader AI revenue monetization and chip demand theme gaining traction across software names.

Indices: CLBT's weight in the NASDAQ 100 and S&P 500 is insufficient to move either index materially. However, niche cybersecurity and public-safety ETFs where CLBT holds higher weight may see modest upside. For broader index context, see the 2026 Global Indices Outlook.

Crypto/Commodities/Forex: No meaningful linkage. FX headwinds (~2pp) reflect non-USD exposure but are too small to influence currency markets.

Trading Considerations

Key levels to watch: Q2 ARR guidance of $510–$513M is the next hard anchor — any Q2 print below $510M ARR would invalidate the re-rating thesis. The AI monetization story hinges on Q2 booking disclosures; if Genesis revenue fails to appear in Q2 results, expect multiple compression. The Q1 earnings beat and outlook upgrade theme supports near-term momentum, but position risk is elevated given GAAP profitability decline and higher opex trajectory. Traders should watch whether management quantifies AI bookings in Q2 guidance revisions as the primary forward catalyst.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.